You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

 

Online download statistics by month:

Online download statistics by month: May 2022 to June 2025

AbstractFullPdf
May 2022418426149
Jun 2022300313126
Jul 202219920271
Aug 202222522873
Sep 202227427985
Oct 202222322785
Nov 202215916163
Dec 202214215576
Jan 202314514552
Feb 202314314687
Mar 202319619787
Apr 2023858550
May 202311311657
Jun 202311311448
Jul 2023696935
Aug 2023888842
Sep 2023818138
Oct 2023818133
Nov 2023929242
Dec 2023748150
Jan 202411211483
Feb 2024939651
Mar 2024118119107
Apr 202410510666
May 2024838454
Jun 2024848447
Jul 202411411557
Aug 2024939142
Sep 202411211244
Oct 202412612768
Nov 202412713061
Dec 202419319585
Jan 202511011152
Feb 202511812158
Mar 202511611872
Apr 202511611664
May 202510310562
Jun 2025696939
Total521252992461